TSE:GEN

GeneNews Competitors

Add
Compare
Today's Range N/A
50-Day Range
C$0.15
MA: C$0.15
C$0.15
52-Week Range N/A
Volume473,147 shs
Average Volume1.48 million shs
Market CapitalizationC$24.65 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

GeneNews (TSE:GEN) Vs. LXG, SQD, SVA, LMD, VPT, and IDL

Should you be buying GEN stock or one of its competitors? Companies in the industry of "diagnostics & research" are considered alternatives and competitors to GeneNews, including LexaGene (LXG), SQI Diagnostics (SQD), Sernova (SVA), LED Medical Diagnostics (LMD), VentriPoint Diagnostics (VPT), and Imaging Dynamics (IDL).

LexaGene (CVE:LXG) and GeneNews (TSE:GEN) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, earnings, institutional ownership, analyst recommendations, risk and profitability.

Earnings and Valuation

This table compares LexaGene and GeneNews' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LexaGeneN/AN/AN/AC($0.12)-6.39
GeneNewsC$234,592.000.00C$-11,557,484.00C($0.07)N/A

LexaGene has higher earnings, but lower revenue than GeneNews. LexaGene is trading at a lower price-to-earnings ratio than GeneNews, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares LexaGene and GeneNews' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
LexaGeneN/AN/AN/A
GeneNewsN/AN/AN/A

Analyst Recommendations

This is a summary of recent recommendations for LexaGene and GeneNews, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
LexaGene0000N/A
GeneNews0000N/A

Summary

GeneNews beats LexaGene on 3 of the 3 factors compared between the two stocks.

SQI Diagnostics (CVE:SQD) and GeneNews (TSE:GEN) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, earnings, institutional ownership, analyst recommendations, risk and profitability.

Earnings and Valuation

This table compares SQI Diagnostics and GeneNews' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SQI DiagnosticsC$977,000.00111.59C$-12,264,984.00C($0.04)-8.89
GeneNewsC$234,592.000.00C$-11,557,484.00C($0.07)N/A

GeneNews has lower revenue, but higher earnings than SQI Diagnostics. SQI Diagnostics is trading at a lower price-to-earnings ratio than GeneNews, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares SQI Diagnostics and GeneNews' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SQI DiagnosticsN/AN/AN/A
GeneNewsN/AN/AN/A

Analyst Recommendations

This is a summary of recent recommendations for SQI Diagnostics and GeneNews, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
SQI Diagnostics0000N/A
GeneNews0000N/A

Sernova (CVE:SVA) and GeneNews (TSE:GEN) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, earnings, institutional ownership, analyst recommendations, risk and profitability.

Earnings and Valuation

This table compares Sernova and GeneNews' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SernovaN/AN/AN/AC($0.03)-54.81
GeneNewsC$234,592.000.00C$-11,557,484.00C($0.07)N/A

Sernova has higher earnings, but lower revenue than GeneNews. Sernova is trading at a lower price-to-earnings ratio than GeneNews, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Sernova and GeneNews' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SernovaN/AN/AN/A
GeneNewsN/AN/AN/A

Analyst Recommendations

This is a summary of recent recommendations for Sernova and GeneNews, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sernova0000N/A
GeneNews0000N/A

Summary

GeneNews beats Sernova on 2 of the 3 factors compared between the two stocks.

LED Medical Diagnostics (CVE:LMD) and GeneNews (TSE:GEN) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, earnings, institutional ownership, analyst recommendations, risk and profitability.

Earnings and Valuation

This table compares LED Medical Diagnostics and GeneNews' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LED Medical DiagnosticsC$14.96 million1.04C$-1,512,615.00C($0.04)-10.26
GeneNewsC$234,592.000.00C$-11,557,484.00C($0.07)N/A

LED Medical Diagnostics has higher revenue and earnings than GeneNews. LED Medical Diagnostics is trading at a lower price-to-earnings ratio than GeneNews, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares LED Medical Diagnostics and GeneNews' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
LED Medical DiagnosticsN/AN/AN/A
GeneNewsN/AN/AN/A

Analyst Recommendations

This is a summary of recent recommendations for LED Medical Diagnostics and GeneNews, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
LED Medical Diagnostics0000N/A
GeneNews0000N/A

Summary

LED Medical Diagnostics beats GeneNews on 3 of the 4 factors compared between the two stocks.

GeneNews (TSE:GEN) and VentriPoint Diagnostics (CVE:VPT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, valuation, profitability, institutional ownership, analyst recommendations, risk and dividends.

Earnings & Valuation

This table compares GeneNews and VentriPoint Diagnostics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GeneNewsC$234,592.000.00C$-11,557,484.00C($0.07)N/A
VentriPoint DiagnosticsC$37,517.001,867.27C$-4,128,201.00C($0.03)-16.97

VentriPoint Diagnostics has lower revenue, but higher earnings than GeneNews. VentriPoint Diagnostics is trading at a lower price-to-earnings ratio than GeneNews, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares GeneNews and VentriPoint Diagnostics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
GeneNewsN/AN/AN/A
VentriPoint DiagnosticsN/AN/AN/A

Analyst Ratings

This is a breakdown of recent recommendations and price targets for GeneNews and VentriPoint Diagnostics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
GeneNews0000N/A
VentriPoint Diagnostics0000N/A

GeneNews (TSE:GEN) and Imaging Dynamics (CVE:IDL) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, valuation, profitability, institutional ownership, analyst recommendations, risk and dividends.

Earnings & Valuation

This table compares GeneNews and Imaging Dynamics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GeneNewsC$234,592.000.00C$-11,557,484.00C($0.07)N/A
Imaging DynamicsC$378,253.0040.98C$-3,927,129.00C($0.02)-3.95

Imaging Dynamics has higher revenue and earnings than GeneNews. Imaging Dynamics is trading at a lower price-to-earnings ratio than GeneNews, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares GeneNews and Imaging Dynamics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
GeneNewsN/AN/AN/A
Imaging DynamicsN/AN/AN/A

Analyst Ratings

This is a breakdown of recent recommendations and price targets for GeneNews and Imaging Dynamics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
GeneNews0000N/A
Imaging Dynamics0000N/A

Summary

Imaging Dynamics beats GeneNews on 3 of the 4 factors compared between the two stocks.


GeneNews Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
LXG
LexaGene
0.5$0.76flatC$83.27 millionN/A-6.39News Coverage
SQD
SQI Diagnostics
0.9$0.32flatC$52.59 millionC$977,000.00-8.89
SVA
Sernova
0.5$1.48flatC$31.35 millionN/A-54.81Gap Down
LMD
LED Medical Diagnostics
0.4$0.40flatC$15.51 millionC$14.96 million-10.26Gap Down
VPT
VentriPoint Diagnostics
0.6$0.56flatC$5.58 millionC$37,517.00-16.97
IDL
Imaging Dynamics
0.4$0.08flatC$4.13 millionC$378,253.00-3.95Gap Down
DXD
3D Signatures
0.5$0.04flatC$2.66 millionN/A-0.91Gap Down
MBI
Med Biogene
0.5$0.05flatC$795,000.00N/A-7.50Gap Up
BUX
(BUX)
0.5N/AN/A$0.00N/A0.00High Trading Volume
Gap Up
IME
12144
0.5N/AN/AC$0.00N/A0.00High Trading Volume
Gap Down
CRL
Charles River Laboratories International
0.5N/AN/A$0.00N/A0.00Gap Up
SENS
Senseonics
0.0N/AN/A$0.00N/A0.00High Trading Volume
This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.